Core Insights - RetinalGenix Technologies Inc. has appointed Dr. Taimour Langaee as a scientific advisor to enhance its DNA GPS Pharmacogenetics initiatives aimed at optimizing personalized treatment pathways for retinal and systemic diseases [1][5] - Dr. Langaee brings over 20 years of experience in pharmacogenomics and precision medicine, overseeing genotyping, sequencing data processing, and clinical genetic association studies [2][3] - The company aims to integrate advanced retinal imaging with pharmacogenetics and AI to identify early signs of chronic diseases, thereby improving overall health management and reducing long-term healthcare costs [6][7] Company Overview - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes by combining genetic screening, advanced imaging, and therapeutic development [9] - The company's proprietary technologies include High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™, which are designed to prevent blindness and detect physiological changes indicating future ocular and systemic diseases [9] Strategic Goals - The integration of Dr. Langaee's expertise is expected to accelerate the company's efforts in delivering personalized, data-driven solutions for retinal and systemic health [5] - RetinalGenix's approach includes remote monitoring and personalized risk assessments based on genetic profiles, which aims to maximize the effectiveness of preventive strategies [7][8]

Company Overview - PMGC Holdings Inc. has filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2025, with the SEC [1] - The company is well-capitalized with a strong balance sheet and a defined business focus [2] Operating Subsidiaries - NorthStrive Biosciences Inc. focuses on developing aesthetic medicines, with its lead asset EL-22 aimed at preserving muscle during weight loss treatments [2] - PMGC Research Inc. utilizes Canadian research grants and collaborates with universities to accelerate scientific discovery [3] - PMGC Capital LLC is a multi-strategy investment firm that seeks undervalued companies and assets to maximize returns [4] Strategic Growth Initiatives - The company is actively pursuing acquisitions of B2B businesses and assets to drive revenue growth and enhance shareholder value [2] - On April 16, 2025, PMGC announced a non-binding Letter of Intent to acquire a cash-flow-positive IT custom packaging company [5] Company Commitment - PMGC is committed to exploring opportunities across various sectors to maximize growth and value [6]

Core Viewpoint - InterDigital (IDCC) is positioned as a strong investment opportunity due to significant revisions in earnings estimates, indicating a positive earnings outlook and potential for continued stock price gains [1][2]. Earnings Estimate Revisions - Analysts have shown increasing optimism regarding InterDigital's earnings prospects, leading to higher earnings estimates which are expected to positively influence the stock price [2]. - The consensus earnings estimate for the current quarter is $2.51 per share, reflecting a decrease of 45.08% from the previous year, but has increased by 66.89% over the last 30 days with no negative revisions [7]. - For the full year, the expected earnings are $11.75 per share, which is a decrease of 21.51% from the prior year, yet the consensus estimate has risen by 15.23% due to three upward revisions and no negative changes [8][9]. Zacks Rank and Performance - InterDigital has achieved a Zacks Rank of 2 (Buy), indicating favorable estimate revisions that suggest strong potential for stock performance [10]. - Historically, stocks with a Zacks Rank of 1 (Strong Buy) and 2 (Buy) have significantly outperformed the S&P 500, with Zacks 1 stocks averaging a 25% annual return since 2008 [3][10]. Recent Stock Performance - Over the past four weeks, InterDigital shares have increased by 7.8%, reflecting investor confidence in the company's earnings growth prospects driven by the positive estimate revisions [11].

截至目前，粤港澳大湾区已有重大科技基础设施10个、国家实验室2家，同时带动了26家国家重点实验室落地广东，吸引了158万研发人员 汇聚大湾区开展前沿性基础研究。 打造人才"强磁场" 共创湾区科技大未来 吸引众多科研人才选择大湾区、扎根大湾区，除了重大科技基础设施之外，还有当地贯穿就业、安居、创业的政策全链条。 央视网消息：近年来，一批批重大科技基础设施和众多科研人才汇聚广东，通过科技创新驱动高质量发展，系列报道《产业变革看广东》 一起跟随总台记者的镜头，探访大湾区的科创世界。先来看大科学装置筑牢南粤创新的"硬核底盘"。 最近，来自香港城市大学的吴桢舵团队在广东东莞松山湖完成了一项用于折叠屏手机铰链的关键材料——先进非晶合金的研究，这项研究 的顺利进行得益于这里建成的我国第一台、全球第四台脉冲式散裂中子源。 在南方科技大学多功能增材制造与4D打印实验室，葛锜教授正带领团队对离心式DLP多材料3D打印技术进行攻关，这一技术可以实现多 材料间近乎零污染的切换，广泛应用于通讯、医学等领域。葛锜教授先后在美国、新加坡求学和任教，2018年底，得知大湾区良好的创新生态 和环境后，葛教授决定回国发展。 吴桢舵告诉记者，随着 ...

Revenue, Adjusted EBITDA2 and EPS above top end of guidanceAll-time record annualized recurring revenue4, up 30% YoYCompany reaffirms full year 2025 guidance WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile, video, and AI technology research and development company, today announced results for the quarter ended March 31, 2025. "In the first quarter, we licensed vivo Mobile, a major smartphone vendor, to drive revenue above the top end of our guidance and increas ...